The July 2026 B2B conference ended with contracts and MoUs focused on local production of vaccines, pharmaceutical raw materials and medical devices.
Cost, scale and concentration make China central to generic APIs. Tariffs, rebates and quality enforcement are changing the picture.
China is the largest international presence in the 2026 exhibitor list. Why that matters for an industry that imports most of its raw materials.
Pakistan makes most of its finished medicines but imports nearly all its active ingredients, mostly from China. The case for localisation, and what…
